DIRS.INFO The most relevant business & tech news

☆ Healthcare companies are promising to help patients quit Wegovy. There's just one problem with that.
▼ + stars: | 2023-12-19 | by ( ) www.businessinsider.com time to read: +11 min

Inkinen said Virta can help patients quit GLP-1 drugs and keep weight off by adjusting the foods they eat to help them feel full, similar to how the drugs reduce feelings of hunger. About 82% of patients taking Wegovy experience gastrointestinal issues like nausea and diarrhea. WeightWatchers didn't provide Business Insider with published data to support its claims that it can help people keep weight off after quitting weight-loss drugs. AdvertisementHe also advises the weight-loss startup Calibrate, which tapers some patients off GLP-1 drugs after they reach a certain body-mass index. GLP-1 drugs also slash the risk of heart attacks, strokes, and cardiac-related death.

Persons: —, Michael Albert, aren't, Sami Inkinen, Inkinen, Virta, Michael Siluk, Noom's, Linda Anegawa, Carolina Rudah, tirzepatide, Mounjaro, Zepbound —, Eli Lilly, Ozempic, Wegovy, Randy Seeley, Seeley, Robyn Phelps, it's, Robert Kushner, Kushner, Florian Gaertner, It's, Albert, Lisa, she's, I'm Organizations: Service, Business, FDA, Virta, Getty, Nordisk, Michigan Nutrition Obesity Research, University of Michigan, Novo Nordisk, Northwestern University Locations: Denver, Michigan

☆ Novo Nordisk's weight loss drug Wegovy slashes risk of serious heart events
▼ + stars: | 2023-11-11 | by ( Angelica Peebles | In Angelicapeebles | ) www.cnbc.com time to read: +2 min

Still life of Wegovy an injectable prescription weight loss medicine that has helped people with obesity. Novo Nordisk's Wegovy cut the risk of serious cardiovascular complications in people with obesity and heart disease in a closely watched trial, demonstrating a particularly large effect on heart attacks, a promising new frontier for the drug. The roughly 17,500-person Select study tested Wegovy in people with obesity and heart disease but who did not have diabetes. The new data could also help the Danish pharmaceutical company maintain its lead over Eli Lilly, whose competing weight-loss drug Zepbound was approved in the U.S. earlier this week. Zepbound has been shown to help people lose more weight, but it hasn't yet demonstrated an effect on cardiovascular outcomes.

Persons: Robert Kushner, Eli Lilly, Zepbound, Howard Weintraub Organizations: Wegovy, American Heart Association Scientific Sessions, New England, of Medicine, Novo Nordisk, Northwestern University Feinberg School of Medicine, Center for, NYU Langone Locations: Danish, U.S

The FDA approved tirzepatide for weight loss under the brand name Zepbound. It has been available as Mounjaro for type 2 diabetes since 2022 and had increasingly been used "off-label" for weight loss while the obesity approval was pending. Zepbound will be available in the U.S. by the end of the year at a list price of $1,059.87 a month, according to Lilly. That compares with a list of $1,349 per-package for Novo Nordisk's (NOVOb.CO) wildly popular weight-loss drug Wegovy. After Wednesday's FDA approval, Lilly can now promote the drug for weight loss.

Persons: Eli Lilly, Mike Segar, Eli Lilly's, ” John Sharretts, Lilly, Morningstar, Damien Conover, Conover, drugmaker, Robert Kushner, Mounjaro, Patrick Wingrove, Leroy Leo, Bhanvi, Shinjini Ganguli, Bill Berkrot Organizations: Company, REUTERS, U.S . Food, Drug Administration, U.S, FDA, FDA’s Center, Drug, Research, Novo Nordisk's, Reuters, Northwestern University Feinberg School of Medicine, Thomson Locations: Branchburg , New Jersey, U.S, Indianapolis, United States, New York, Bengaluru

Wegovy is a weekly injection that can help patients shed 15% of their weight alongside diet and exercise changes. Walgreens (WBA.O), one of the biggest U.S. pharmacies, is experiencing supply shortages for the higher strengths, spokesperson Erin Loverher confirmed. Doctors in six U.S. states told Reuters patients are reporting problems filling their prescriptions for the higher doses. Three of the doctors said supply delays at pharmacies had resulted in patients missing their Wegovy injections at the prescribed weekly interval. "Patients are often having to delay their injections because it's harder for pharmacies to get Wegovy in stock," he said.

Persons: Erin Loverher, Novo, Alicia Shelly, Shelly, Robert Kushner, Wegovy, Kushner, Denise Wells, Wells, Holly Lofton, New York University Langone, Disha Narang, Narang, Maggie Fick, Patrick Wingrove, Elissa Welle, Caroline Humer, Bill Berkrot Organizations: Reuters, Walgreens, Wellstar, Northwestern University's Feinberg School of Medicine, Amazon Pharmacy, New York University, Northwestern Medicine, Barclays Research, Novo, Thomson Locations: U.S, Danish, Georgia, Chicago, Michigan, Chicago , New York, San Francisco, Detroit, Atlanta, Charlottesville , Virginia, London, New York

Participants who were offered cash incentives for either pounds lost or for completing certain activities were more likely to lose weight compared with those who were simply offered tools, such as diet books, fitness trackers and access to a weight loss program, the study found. On average, participants in the goal-directed group earned $440.44, as compared to $303.56 in the outcome-based group. “Even if less weight is lost, adopting lifelong physical activity or better eating habits may be more important,” she said. Kushner, who was not involved with the new study, agreed that low-income people face extra challenges when it comes to weight loss. What’s not clear, however, is how the strategy of offering cash for weight loss could be implemented in a real-world setting, outside of academia.

Search resuls for: "Robert Kushner"

5 mentions found